ocrelizumab.
anti-CD20 monoclonal antibody under development for treatment of B cell leukemia and multiple sclerosis
Roche beats sales forecasts, reaffirms outlook
Roche Q3 sales reached 16.13 billion Swiss francs, beating the roughly 15.8 billion franc analyst estimate, and the company reaffirmed its 2026 outlook.
Business · 8 sources · Oct 22, 2026Read itThe journal
Open the journal →The conversation starts in the journal — be the first to post.
About ocrelizumab
Ocrelizumab, sold under the brand name Ocrevus, is a medication used for the treatment of multiple sclerosis. It is a humanized anti-CD20 monoclonal antibody. It targets CD20 marker on B lymphocytes and is an immunosuppressive drug. Ocrelizumab binds to an epitope that overlaps with the epitope to which rituximab binds. It is administered by intravenous infusion. The fixed-dose combination ocrelizumab/hyaluronidase is administered by subcutaneous injection.
Everything about ocrelizumab →